A Snapshot of a Paradigm Shift in the Systemic Therapeutic of HBP Cancers, What to Do and Where to Go Next?

Paradigm Shift in HBP Cancer Therapeutics

Authors

  • Maple Ye Feng Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, China
  • Stephen Lam Chan Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, China. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

Keywords:

Hepatopancreatibiliary (HPB) cancer, Hepatocellular carcinoma (HCC), Biliary tract cancers (BTCs), Pancreatic ductal adenocarcinoma (PDAC)

Author Biographies

Maple Ye Feng, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, China

Dr. Maple Ye Feng is an Associate Editor of HBP Cancer International and a dedicated physician who specializes in Medical Oncology. She obtained her PhD from the University of Hong Kong and holds an MRCP(UK). Dr. Feng completed her clinical training in Advanced Internal Medicine and Medical Oncology at Princess Margaret Hospital and Prince of Wales Hospital in Hong Kong. Currently, she serves as an honorary academic scholar at the Department of Clinical Oncology at the Chinese University of Hong Kong. Dr. Feng's research interests lie in both scientific and clinical aspects of cancer management, with the aim of bridging the gap between benchside and bedside for the benefit of cancer patients.

Stephen Lam Chan, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, China. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

Dr. Stephen L. Chan is the Associate Clinical Professor of the Department of Clinical Oncology in the Chinese University of Hong Kong. He graduated from the University of Hong Kong in 2000 and obtained specialist qualification in Medical Oncology in 2007. He has been awarded the Gold Medal Prize for Dissertation in 2007 and the Young Investigator award in 2008 by the Hong Kong College of Physician. His main research area is on clinical and traditional research for gastrointestinal cancers, especially hepatobiliary and pancreatic cancers.

Dr. Chan has published over 100 publications including 5 first-authored articles in the Journal of Clinical Oncology as well as comments in the Lancet. He has been the principal investigator of a number of clinical trials including projects funded by the General Research Fund, University Grant Committee in Hong Kong, Innovation and Technology Fund, and Hong Kong Health and Research Fund of the Hong Kong Government, as well as international grants such as the Sister Institution Network Fund of MD Anderson Center for Cancer.

References

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;77:1598–606. https://doi.org/10.1016/j.jhep.2022.08.021.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. https://doi.org/10.3322/caac.21492.

Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012;43:1552–8. https://doi.org/10.1016/j.humpath.2011.12.007.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72–9. https://doi.org/10.1634/theoncologist.2011-0386.

Pauff JM, Papadopoulos KP, Janku F, Turk AA, Goyal L, Shroff RT, et al. A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors. JCO 2021;39:TPS350–TPS350. https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS350.

Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009;158:1–9. https://doi.org/10.1111/j.1365-2249.2009.03992.x.

Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418–25. https://doi.org/10.1038/sj.bjc.6604129.

Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006;15:525–32.

Rahnemai-Azar AA, Weisbrod AB, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Rev Gastroenterol Hepatol 2017;11:439–49. https://doi.org/10.1080/17474124.2017.1309290.

Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25–34. https://doi.org/10.1158/2159-8290.CD-14-0765.

Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234–43. https://doi.org/10.1016/S1470-2045(20)30321-1.

Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261–73. https://doi.org/10.1016/S1470-2045(22)00541-1.

Fischmann TO, Smith CK, Mayhood TW, Myers JEJr, Reichert P, Mannarino A, et al. Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors. Biochemistry 2009;48:2661–74. https://doi.org/10.1021/bi801898e.

Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383. https://doi.org/10.1371/journal.pone.0115383.

Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol 2020:JCO2001364. https://doi.org/10.1200/JCO.20.01364.

Strickler JH, Satake H, Hollebecque A, Sunakawa Y, Tomasini P, Bajor DL, et al. First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. JCO 2022;40:360490–360490. https://doi.org/10.1200/JCO.2022.40.36_suppl.360490.

Downloads

Published

2023-07-15

How to Cite

Feng, M. Y., & Chan, S. L. (2023). A Snapshot of a Paradigm Shift in the Systemic Therapeutic of HBP Cancers, What to Do and Where to Go Next? Paradigm Shift in HBP Cancer Therapeutics. HPB Cancer International, 1(1), 1–3. Retrieved from https://rasayely-journals.com/index.php/hpbci/article/view/56

Issue

Vol. 1 No. 1 (2023)

Section

Editorial

License

Copyright (c) 2023 Maple Ye Feng, Stephen Lam Chan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright of their manuscripts, and all Open Access articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.